ABOUT US About Celltrion Notice Media Center BUSINESS Business Areas R&D Production Distribution PRODUCTS Products Pipeline ESG Environmental Social Governance ESG Archive IR Financial Information Stock Summary Public Disclosures IR Archive CAREERS Our Values How to Apply Jobs KOR ENG Choose Other Countries Europe Asia Pacific North America Latin America close Denmark Finland (FI) Finland (SV) France Germany Hungary Ireland Italy Netherlands Norway (NO) Norway (SV) Sweden Swiss Turkey United Kingdom Korea (HQ) Korea (EN) Japan Australia Canada (EN) Canada (FR) USA Brazil Colombia Chile Peru Mexico
Category IR Approvals General Other Category▾CategoryIRApprovalsGeneralOther All Title Content All▾AllTitleContent delete search Other Notice to Shareholders [Guideline for Implementing the Shareholder Return Plan that Prioritizes Enhancing Shareholder Value] 2025.04.02 Top-pinned content General Notice to Shareholders [UPDATE - Company's Position and Response Strategy Regarding the U.S. Trump Administration's Tariff Policy(2)] 2025.02.19 Top-pinned content General Notice to Shareholders [Response Strategy to the U.S. Trump Administration’s Tariff Policy on Pharmaceuticals] 2025.01.30 Top-pinned content Other Notice to Shareholders [Guideline for Implementing the Shareholder Return Plan that Prioritizes Enhancing Shareholder Value] 2025.04.02 General Notice to Shareholders [UPDATE - Company's Position and Response Strategy Regarding the U.S. Trump Administration's Tariff Policy(2)] 2025.02.19 General Notice to Shareholders [Response Strategy to the U.S. Trump Administration’s Tariff Policy on Pharmaceuticals] 2025.01.30 General Notice to Shareholders Regarding Updates on Our Business Progress 2024.12.04 General Details on Accessing the Hong Kong Investor Day Session 2024.11.26 IR Notice to Shareholders (Regarding the latest business progress and outlook) 2024.11.16 IR Notice to Shareholders (Regarding the recent progress and business outlook) 2024.10.18 IR Notification Regarding Review Results of Merger Proposal 2024.08.16 General Latest Updates on Agreements with PBMs for Zymfentra 2024.08.05 General Responses to Inquiries regarding the Inclusion of Zymfentra in PBM Formularies 2024.08.01 First 1 2 3 Last